Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patients' Preferences for Primary Immune Thrombocytopenia Treatment

NCT07786077 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07786077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07786077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
December 8, 2025
Completion date
December 15, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune thrombocytopenia